"Stefan Oelrich has been a member of the Board of Management of Bayer AG and Head of the Pharmaceuticals Division, headquartered in Berlin, Germany, since November 1, 2018." (source)
Oelrich (1:37:26): "For us, therefore, we're really taking that leap, us as a company, Bayer, in cell and gene therapy, which to me is one of these examples where we're really going to make a difference, hopefully, moving forward.
Ultimately, the mRNA vaccines are an example for that cell and gene therapy. I always like to say, if we had surveyed two years ago, in the public, 'Would you be willing to take a gene or cell therapy and inject it into your body?’, we would have probably had a 95% refusal rate.
I think this pandemic has also opened many people's eyes to innovation in a way that was maybe not possible before.”
© Copyright World Health Organization (WHO), 2021. All Rights Reserved.
Copyright notice
https://www.who.int/about/policies/terms-of-use